HOME    |    SITEMAP    |    CONTACT    |    

Share  | 

News   ( View All )


  • 06/24/14 - Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates  Read More
  • 04/07/14 - Mersana Therapeutics Enters Collaboration with Takeda to Develop Next-Generation Antibody-Drug Conjugates  Read More
  • 04/03/14 - Mersana to Present at Annual Meeting of the American Association of Cancer Research  Read More

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes.


Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next-generation drugs with best-in-class potential to address multiple unmet needs in oncology. Our versatile conjugation system integrates Fleximer®, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Our technology is being leveraged in multiple therapeutic areas through partnerships.